Tildrakizumab Treatment for Psoriasis in Real-world Practice: An Analysis from the Swiss Registry (SDNTT)
Year: 2024
Type: article
Study design: Observational Study
Abstract: Real-world data on the effectiveness and safety of tildrakizumab, an interleukin 23p19 inhibitor, in Switzerland is limited. The objectives of this analysis were to assess the effectiveness and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis in Switzerland. Twenty-eight adults from the Swiss Dermatology Network for Targeted Therapies registry (SDNTT), who were on tildrakizumab treatment and had at least 3 months' follow-up, were enrolled in this prospective, multicentre study. No missing data imputation was performed. The median Psoriasis Area and Severity Index (PASI) decreased from 9.5 at baseline to 2.1 and 0.3 (both p < 0.001) after 3 and 18 months, respectively, of tildrakizumab treatment. After 3 months, 76.9%/30.8% patients reached an absolute PASI < 3/ < 1. These rates increased to 85.7%/57.1% after 18 months of treatment. The proportions of patients achieving PASI 90/100 responses were 47.8%/30.4% at month 6 and 42.9%/14.3% at month 18. A significant improvement in quality of life up to 18 months of follow-up was observed as measured by the Dermatology Life Quality Index. There were no treatment discontinuations due to adverse events. This real-world registry provides robust evidence supporting the long-term effectiveness and favourable safety profile of tildrakizumab in treating patients with moderate-to-severe psoriasis.
Source: Acta Dermato Venereologica
Authors: Julia-Tatjana Maul, Melike Ak, Sara E. Cerminara, Simona Steinmann, Elisabeth V. Goessinger, Anna Darzina, Iker Oyanguren Monferrer, Raphael Micheroli, Georgios Kokolakis, Elisabeth Roider, Felix Oestereich, Eva Mateu, Martina Burlando, Alexander A. Navarini, Thomas Kündig, Lara Valeska Maul
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $1,725
Funders: National Science Foundation, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Sanofi, L'Oreal USA, Biogen, Celgene, Regeneron Pharmaceuticals, Les Laboratories Pierre Fabre, MannKind Corporation, Allergy Therapeutics, Incyte, XBiotech, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Galderma, Basilea Pharmaceutica, LEO Pharma, Sanofi Genzyme, UCB Pharma, Actelion Pharmaceuticals, Cilag
OpenAlex ID: W4404763396